ClinicalTrials.gg
TerminatedNCT02179177Updated Mar 11, 2020Results posted

Apixaban in Patients With Sickle Cell Disease

A Phase 3 interventional study of Apixaban and Placebo in Vaso-occlusive Crisis, Reduction in Hospitalizations and Sickle Cell Disease, sponsored by Nirmish Shah. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Nirmish Shah · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
funding has been exhausted

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Enrollment
45th of 56
16 · median 63
Started
2015
with 4 others
Phase 3
17 of 60
3 open now
Registered
21st of 60
by date

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 45th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2015, is one of 17 in phase 3, and was the 21st registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs. This study attempts to critically avoid admissions by reducing daily pain scores and pain crisis as an outpatient by use of a novel oral anticoagulant.

Read the detailed description

There is not only significant morbidity associated with patients with SCD, but also costs associated with the numerous hospitalizations. Small studies have been unable to show clear benefit of the use of low dose anticoagulation in SCD due to limited sample size or the inclusion of very specific populations. However, studies have shown a decrease in the level of elevated prothrombotic markers with anticoagulation, and one study using full dose anticoagulation in patients with a generally milder form of SCD (with high protective hemoglobin) showed more rapid decrease in clinical pain with use of anticoagulation, suggesting a possible benefit of such therapy. Due to the paucity of data to support therapeutic dose LMWH in the more severe forms of SCD seen in the United States, we have chosen prophylactic dose anticoagulation. This study proposal attempts to critically avoid admissions by reducing daily pain scores and pain crisis as an outpatient by use of a novel oral anticoagulant.

The development of novel anticoagulants such as oral direct factor Xa (FXa) inhibitors allows the realistic use of daily prophylactic dosing as an outpatient. Past studies as detailed earlier have been limited by attempts to use subcutaneous injections or frequent, close monitoring for acenocoumarol treatment, both which are not ideal for chronic daily use. Furthermore, the use of global assays such calibrated automated thrombography (CAT) have shown further details about thrombin generation in a population which is hypercoagulable at baseline.

This is a double blind, parallel group, placebo controlled feasibility study with an enrollment target of 25 patients (12 per arm). All subjects that meet inclusion criteria as an outpatient, following a 1 month observation, will be randomized to receive an oral prophylactic dose factor Xa inhibitor (Apixaban 2.5mg po bid) or placebo for 6 months. Subjects will return for a 30 day (+/- 5 days) follow-up visit after the End of Treatment (EOT) visit. Initial randomization will occur by computerized randomization technique by the investigational drug services (IDS) at Duke University Medical Center.

03

Conditions studied

  • Vaso-occlusive Crisis
  • Reduction in Hospitalizations
  • Sickle Cell Disease

Keywords

  • Vaso-occlusive crisis
  • Reduction in hospitalizations
  • Sickle Cell Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented HgbSS, SC or HgbS-beta0 thalassemia,
  • age ≥18 years old and ≤80,
  • seen in outpatient clinic ≥2 times in past year
  • seen for an acute care visit (hospitalization, emergency department, or day hospital visit) for pain >2 times in the past year.

Exclusion criteria

Exclusion Criteria:

  • Hospitalization or day hospital visit for pain crisis within the past 2 weeks
  • Patients with ≥10 acute care visits within the past year will be excluded
  • Creatinine >3.0 mg/dL
  • creatinine ≥1.5 mg/dL AND weight ≤60 kg
  • chronic use of antiplatelet or anticoagulation medication
  • Patients with known vasculopathy or Moya-Moya
  • count \<100 X 109/L
  • or ALT >3 times normal
  • chronic red blood cell transfusions (scheduled transfusions)
  • packed red blood cell transfusion within the past 2 months
  • Use of and P-gp inhibitor medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Apixaban

    Active drug Apixaban 2.5mg taken by mouth twice a day

    Drug: Apixaban

  • Placebo comparator
    Placebo

    Sugar pills that look like Apixaban that will be taken by mouth twice a day

    Drug: Placebo

Interventions

  • Drug is taken by mouth twice a day for 6 months

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change in Pain as Measured by Visual Analog Scale (VAS)

    The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with "0" corresponding to no pain at one end and "10" indicating the worst pain at the other.

    Time frame: Month 1 to Month 8

Secondary outcomes

  1. Change in Thrombin Generation Using D-dimer Measurement as a Surrogate

    Time frame: Enrollment to 2 months

  2. Daily Pain Scores While Hospitalized as Measured by VAS

    The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with "0" corresponding to no pain at one end and "10" indicating the worst pain at the other. Secondary analysis will be performed to evaluate differences when patients are hospitalized and on study drug versus placebo.

    Time frame: up to 8 months

  3. Number of Hospitalizations During Treatment

    Time frame: up to 8 months

07

Results

Posted Mar 11, 2020

Participant flow

Patients with sickle cell disease were enrolled as an outpatient in clinic while at baseline pain from January 2015 to September 2017.

Participant flow — Overall Study
MilestoneApixabanPlacebo
Started88
Completed66
Not completed22
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange in Pain as Measured by Visual Analog Scale (VAS)

The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with "0" corresponding to no pain at one end and "10" indicating the worst pain at the other.

Time frame:
Month 1 to Month 8
Reported as:
Mean · score on a scale
Change in Pain as Measured by Visual Analog Scale (VAS)
score on a scaleApixabanPlacebo
Change in Pain as Measured by Visual Analog Scale (VAS)-1 ± 0.50 ± 0.4
Statistical analysis
  • Apixaban vs Placebo · t-test, 2 sided · p = 0.11 · Mean difference (net): 1
SecondaryChange in Thrombin Generation Using D-dimer Measurement as a Surrogate
Time frame:
Enrollment to 2 months

No measurements were reported for this outcome.

SecondaryDaily Pain Scores While Hospitalized as Measured by VAS

The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with "0" corresponding to no pain at one end and "10" indicating the worst pain at the other. Secondary analysis will be performed to evaluate differences when patients are hospitalized and on study drug versus placebo.

Time frame:
up to 8 months
Reported as:
Mean · score on a scale
Daily Pain Scores While Hospitalized as Measured by VAS
score on a scaleApixabanPlacebo
Daily Pain Scores While Hospitalized as Measured by VAS6.4 ± 3.46.6 ± 3.8
SecondaryNumber of Hospitalizations During Treatment
Time frame:
up to 8 months
Reported as:
Mean · hospitalizations
Number of Hospitalizations During Treatment
hospitalizationsApixabanPlacebo
Number of Hospitalizations During Treatment3 ± 3.31.5 ± 1.5

Adverse events

Collected over 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban0/8 (0%)2/8 (25%)2/8 (25%)
Placebo0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent serious events
Most frequent serious events
EventApixabanPlacebo
PregnancyPregnancy, puerperium and perinatal conditions1/80/8
HospitalizationSurgical and medical procedures1/80/8
Most frequent other events
Most frequent other events
EventApixabanPlacebo
Sickle Cell CrisisCardiac disorders1/80/8
Sickle Cell CrisisMusculoskeletal and connective tissue disorders1/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)ApixabanPlaceboTotal
Mean30 ± 6.233 ± 3.931.5 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanPlaceboTotal
Female5510
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ApixabanPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino000
Unknown or Not Reported8816
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ApixabanPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American8816
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)ApixabanPlaceboTotal
United States8816
08

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 2 years 6 months after primary completion. A results delay was requested in Mar 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2014
First posted
Jul 1, 2014
Start
Jan 2015
Primary completionActual
Sep 3, 2017
CompletionActual
Sep 3, 2017
Results delay requested
Mar 26, 2019
Results first posted
Mar 11, 2020
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02179177
Lead sponsor
Nirmish Shah
Responsible party
Nirmish Shah (Assistant Professor, Duke University) — Sponsor-investigator
First posted
Jul 1, 2014
Start date
Jan 2015
Primary completion
Sep 3, 2017
Completion
Sep 3, 2017
Results posted
Mar 11, 2020
Last update
Mar 11, 2020

Study contacts

Nirmish Shah, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion